6-amino-N-[6-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-10,15,20,25,30,35-hexakis[[6-(6-aminohexanoylamino)hexanoylamino]methyl]-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methylamino]-6-oxohexyl]hexanamide | 1086534-83-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-amino-N-[6-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-10,15,20,25,30,35-hexakis[[6-(6-aminohexanoylamino)hexanoylamino]methyl]-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methylamino]-6-oxohexyl]hexanamide
• CAS: 1086534-83-9
• 化学式: C₁₂₆H₂₃₁N₂₁O₄₂
• 分子量: 2712.34
• InChiKey: LBMZMEHIQBFKCV-ZSEIRTOCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -12.3
• 重原子数：
  189
• 可旋转键数：
  91
• 环数：
  21.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  1000
• 氢给体数：
  35
• 氢受体数：
  49

反应信息

• 作为产物：
  描述：

  在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 6-amino-N-[6-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-10,15,20,25,30,35-hexakis[[6-(6-aminohexanoylamino)hexanoylamino]methyl]-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methylamino]-6-oxohexyl]hexanamide
  参考文献：
  名称：

  Folate-Appended β-Cyclodextrin as a Promising Tumor Targeting Carrier for Antitumor Drugs in Vitro and in Vivo

  摘要：

  A large number of antitumor drug delivery carriers based on passive targeting and/or active targeting have been developed. However, encapsulation of antitumor drugs into these drug carriers is often complicated, and antitumor activities of these targeting systems are not satisfactory. In the present study, we first prepared heptakis-6-folic acid (FA)-appended beta-cyclodextrin (beta-CyD) possessing two caproic acids between FA and a beta-CyD molecule as a spacer (Fol-c(2)-beta-CyD) and evaluated the potential as a novel tumor targeting carrier for antitumor drugs through a complexation. Fol-c(2)-beta-CyD formed an inclusion complex with doxorubicin (DOX) at a 1:1 molar ratio with a markedly high stability constant (>10(6) M-1). Cellular uptake of DOX was increased by the addition of Fol-c(2)-beta-CyD in KB cells, a folate receptor-alpha (FR-alpha)-positive cell line. Additionally, Fol-c(2)-beta-CyD increased in vitro antitumor activities of antitumor drugs such as DOX, vinblastine (VBL), and paclitaxel (PTX) in KB cells, but not in A549 cells, a FR-alpha-negative cell line. The complex of DOX with Fol-c(2)-beta-CyD markedly increased antitumor activity of DOX, not only after intratumoral administration but also after intravenous administration to mice subcutaneously inoculated Colon-26 cells, a FR-alpha-positive cell line. These findings suggest that Fol-c(2)-beta-CyD could be useful as a promising antitumor drug carrier.

  DOI：

  10.1021/bc400015r

文献信息

• Folate-Appended β-Cyclodextrin as a Promising Tumor Targeting Carrier for Antitumor Drugs <i>in Vitro</i> and <i>in Vivo</i>
  作者：Ayaka Okamatsu、Keiichi Motoyama、Risako Onodera、Taishi Higashi、Takahiro Koshigoe、Yasutaka Shimada、Kenjiro Hattori、Tomoko Takeuchi、Hidetoshi Arima

  DOI：10.1021/bc400015r

  日期：2013.4.17

  A large number of antitumor drug delivery carriers based on passive targeting and/or active targeting have been developed. However, encapsulation of antitumor drugs into these drug carriers is often complicated, and antitumor activities of these targeting systems are not satisfactory. In the present study, we first prepared heptakis-6-folic acid (FA)-appended beta-cyclodextrin (beta-CyD) possessing two caproic acids between FA and a beta-CyD molecule as a spacer (Fol-c(2)-beta-CyD) and evaluated the potential as a novel tumor targeting carrier for antitumor drugs through a complexation. Fol-c(2)-beta-CyD formed an inclusion complex with doxorubicin (DOX) at a 1:1 molar ratio with a markedly high stability constant (>10(6) M-1). Cellular uptake of DOX was increased by the addition of Fol-c(2)-beta-CyD in KB cells, a folate receptor-alpha (FR-alpha)-positive cell line. Additionally, Fol-c(2)-beta-CyD increased in vitro antitumor activities of antitumor drugs such as DOX, vinblastine (VBL), and paclitaxel (PTX) in KB cells, but not in A549 cells, a FR-alpha-negative cell line. The complex of DOX with Fol-c(2)-beta-CyD markedly increased antitumor activity of DOX, not only after intratumoral administration but also after intravenous administration to mice subcutaneously inoculated Colon-26 cells, a FR-alpha-positive cell line. These findings suggest that Fol-c(2)-beta-CyD could be useful as a promising antitumor drug carrier.